// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

TGFß1-induces resistance to apoptosis in human lung myofibroblasts via TRPA1 downregulation

Harvinder Virk - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The effect of mast cell stabilisation in a large animal model of pulmonary fibrosis

S Nimanthi Vithana Dewage - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary fibrosis

Pirfenidone

Validation of the IPF-specific version of St. George’s Respiratory Questionnaire in Danish

Thomas Skovhus Prior - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Dyspnea

N/A

Temporal changes in mediastinal lymphadenopathy in patients with idiopathic pulmonary fibrosis

Katarina Pontoppidan - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

The utilization pattern of surgical lung biopsies (SLB) for the diagnosis of interstitial lung diseases (ILD) in Sri Lanka

Amila Rathnapala - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Using a selective avß6 PET ligand to optimise early phase IPF clinical trials

Juliet Simpson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Adherence to home spirometry among patients with IPF: results from the INMARK trial

Imre Noth - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nintedanib

Decline in 4-metre gait speed (4MGS) over 6 months is associated with mortality in IPF

Claire M. Nolan - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial

Gisli Jenkins - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nintedanib

Differences between ANCA positive and negative lung fibrosis cases without vasculitis

Nesrin Mogulkoc - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre

Conal Hayton - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF)

Mirjam J.G. van Manen - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) – modelling the myth

Marlies Wijsenbeek - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Development of a patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF)

Anne-Marie Russell - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Effect of delayed secondary care referral on morbidity and mortality in idiopathic pulmonary fibrosis patients treated with antifibrotics

Hon Lin Wu - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Interstitial lung disease at a district general hospital: When are patients referred to tertiary care?

Matthew John Burton - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

What proportion of patients with Idiopathic Pulmonary Fibrosis fall outside UK prescribing criteria for anti-fibrotic treatment? A UK specialist centre review

Christopher J Brereton - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Impact of compliance and specialist nurse support on IPF survival in patients commenced on antifibrotic therapy

David Anderson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Episodes of Acute Respiratory Deterioration in patients with idiopathic pulmonary fibrosis in the UK – mortality and contributing factors

Michael Marcus - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

TRPA1 ion channel expression in human lung myofibroblasts

H Virk - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved